CURE — Biocure Technology Share Price
Last trade - 00:00- CA$0.16m
- -CA$0.09m
Momentum
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 0.55 | ||
| Price to Tang. Book | 0.55 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -31.87% | ||
| Return on Equity | -39.24% | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 30th Sep | Unit | 2005 | 2006 | 2007 | 2008 | 2009 | 2010E | 2011E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | CA$m | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Health Trend(F-Score)
Bankruptcy Score(Z-Score)
Earnings Manipulation Risk(M-Score)
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Biocure Technology Inc. is a Canada-based biotech company that is developing its CAR-T cell therapy for leukemia, lung, breast and pancreatic cancer. The Company focuses on developing and commercializing various biopharmaceutical technologies relating to uses of recombinant and ranibizumab. The Company in the process of pre-clinical trials of five biosimilar products in South Korea, including Interferon Beta 1b, PEG- Filgrastim as well as Ranibizumab. Interferon Beta 1b is used for treating relapsing forms of multiple sclerosis (MS). Filgrastim is used to treat neutropenia, a lack of certain white blood cells caused by bone marrow transplants, chemotherapy, and other conditions. Ranibizumab is used for treating macular degeneration and is also used to treat a type of eye problem known as macular edema, as well as certain eye problems caused by diabetes. The Company is also engaged in a mineral exploration property project through a limited partnership.
Directors
- Address
- 300-1055 West Hastings Street, VANCOUVER, V6E 2E9
- Web
- https://biocuretech.com/
- Phone
- +1 6046097149
- Auditors
- BDO Canada LLP
Similar to CURE
American Future Fuel
Canadian Securities Exchange
Appia Rare Earths & Uranium
Canadian Securities Exchange
First Uranium Resources
Canadian Securities Exchange
Labrador Uranium
Canadian Securities Exchange
Madison Metals
Canadian Securities Exchange
FAQ
As of Today at 19:03 UTC, shares in Biocure Technology are trading at CA$0.04. This share price information is delayed by 15 minutes.
Shares in Biocure Technology last closed at CA$0.04 and the price had moved by -80% over the past 365 days. In terms of relative price strength the Biocure Technology share price has underperformed the Toronto Stock Exchange 300 Composite Index by -79.66% over the past year.
There is no consensus recommendation for this security.
Biocure Technology does not currently pay a dividend.
Biocure Technology does not currently pay a dividend.
Biocure Technology does not currently pay a dividend.
To buy shares in Biocure Technology you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of CA$0.04, shares in Biocure Technology had a market capitalisation of CA$0.16m.
Here are the trading details for Biocure Technology:
- Country of listing: Canada
- Exchange: CNX
- Ticker Symbol: CURE
Based on an overall assessment of its quality, value and momentum Biocure Technology is currently classified as a . The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
We could not find analyst target price data for this security.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Biocure Technology. Over the past six months, its share price has underperformed the Toronto Stock Exchange 300 Composite Index by -52.97%.
As of the last closing price of CA$0.04, shares in Biocure Technology were trading -74.67% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Biocure Technology PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at CA$0.04.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
We do not have data on Biocure Technology's directors